Yinghua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yinghua Li has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Muqing Liu
School of Information Science and Technology, Fudan University, Shanghai, China
5 shared publications Ke Xu
Department of Orthopedics, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China; Shanghai Clinical Research Center for Aging and Medicine, Shanghai, China; Center of Community-Based Health Research, Fudan University, Shanghai, China
4 shared publicationsHui Jiang
Academy for Engineering and Technology, Fudan University, 220th Handan Road, Shanghai 200433, China
3 shared publicationsWenchao Fei
Department of Orthopedics, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China; Shanghai Clinical Research Center for Aging and Medicine, Shanghai, China; Center of Community-Based Health Research, Fudan University, Shanghai, China
3 shared publications- Yang Hong
Department of Orthopedics, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China; Shanghai Clinical Research Center for Aging and Medicine, Shanghai, China; Center of Community-Based Health Research, Fudan University, Shanghai, China
3 shared publications Haokuan Qin
Institute of Future Lighting, Academy for Engineering & Technology, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 18 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 172, 116233
4,4′-Dimethoxychalcone ameliorates estrogen-deficient osteoporosis by targeting PTP1B to inhibit the c-Src/NFATc1 signaling axis
- 18 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 172, 116233
Open Access4,4′-Dimethoxychalcone ameliorates estrogen-deficient osteoporosis by targeting PTP1B to inhibit the c-Src/NFATc1 signaling axis
- 17 November 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 580, 120706
Corrigendum to “The diagnostic value of Renalase level in serum for chronic kidney disease with different stages” [Clin. Chim. Acta 578 (2025) 120561]
- 17 November 2025
- Published by Elsevier in Clinica Chimica Acta
- Vol. 580, 120706
Corrigendum to “The diagnostic value of Renalase level in serum for chronic kidney disease with different stages” [Clin. Chim. Acta 578 (2025) 120561]
- Open Access
- 1 January 2025
- Published by Discovery Medicine in Discovery Medicine
- Vol. 37 (201) , 2455-2474
Sodium Hydrosulfide Alleviates Osteoporosis by Suppressing Osteoclastogenesis via the Inhibition of the NF-κB Signaling
Background: While existing pharmacotherapies for osteoporosis, such as bisphosphonates, reduce fracture risk, their long-term use remains limited by adverse effects, including gastrointestinal toxicity, osteonecrosis of the jaw, and atypical femoral fractures. Hydrogen sulfide (H2S), an endogenous gasotransmitter with anti-inflammatory properties, emerges as a potential alternative, but the role of its donor, sodium hydrosulfide (NaHS), in osteoporosis remains unexplored. Therefore, this study investigates NaHS-driven bone-protective mechanisms, emphasizing its ability to modulate the nuclear factor kappa-B (NF-κB)/ inhibitor of NF-κB alpha (IκB-α) axis—a crucial pathway in osteoclastogenesis. Methods: Mice were divided into a sham control group (n = 6) and an ovariectomized (OVX) group (n = 6). Mice in the OVX group received varying doses of NaHS (0, 0.38, 0.75, 1.5 mg/kg/day) or vehicle for 4 weeks. Bone mineral density (BMD) was quantified using micro-computed tomography (micro-CT) analysis. Osteoclast differentiation was assessed in bone marrow-derived macrophages (BMMs) and RAW264.7 cells via tartrate-resistant acid phosphatase (TRAP) staining. Molecular mechanisms were deciphered using ubiquitination assays, nuclear/cytoplasmic fractionation, and immunofluorescence. Results: NaHS treatment increased lumbar BMD and trabecular bone-to-tissue volume in OVX mice compared to untreated controls. In vitro, NaHS (0.15 mM) significantly suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis (p < 0.05). Mechanistically, for the first time, NaHS was found to stabilize IκB-α by inhibiting its ubiquitination, thereby blocking the nuclear translocation of NF-κB p65. Conclusions: NaHS mitigates OVX-induced bone loss via dual inhibition of osteoclast differentiation (through IκB-α/NF-κB blockade) and bone resorption. Its capacity to circumvent the limitations of current therapies positions NaHS as a novel candidate for osteoporosis management.
- 1 January 2025
- Published by Discovery Medicine in Discovery Medicine
- Vol. 37 (201) , 2455-2474
Open AccessSodium Hydrosulfide Alleviates Osteoporosis by Suppressing Osteoclastogenesis via the Inhibition of the NF-κB Signaling
Background: While existing pharmacotherapies for osteoporosis, such as bisphosphonates, reduce fracture risk, their long-term use remains limited by adverse effects, including gastrointestinal toxicity, osteonecrosis of the jaw, and atypical femoral fractures. Hydrogen sulfide (H2S), an endogenous gasotransmitter with anti-inflammatory properties, emerges as a potential alternative, but the role of its donor, sodium hydrosulfide (NaHS), in osteoporosis remains unexplored. Therefore, this study investigates NaHS-driven bone-protective mechanisms, emphasizing its ability to modulate the nuclear factor kappa-B (NF-κB)/ inhibitor of NF-κB alpha (IκB-α) axis—a crucial pathway in osteoclastogenesis. Methods: Mice were divided into a sham control group (n = 6) and an ovariectomized (OVX) group (n = 6). Mice in the OVX group received varying doses of NaHS (0, 0.38, 0.75, 1.5 mg/kg/day) or vehicle for 4 weeks. Bone mineral density (BMD) was quantified using micro-computed tomography (micro-CT) analysis. Osteoclast differentiation was assessed in bone marrow-derived macrophages (BMMs) and RAW264.7 cells via tartrate-resistant acid phosphatase (TRAP) staining. Molecular mechanisms were deciphered using ubiquitination assays, nuclear/cytoplasmic fractionation, and immunofluorescence. Results: NaHS treatment increased lumbar BMD and trabecular bone-to-tissue volume in OVX mice compared to untreated controls. In vitro, NaHS (0.15 mM) significantly suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis (p < 0.05). Mechanistically, for the first time, NaHS was found to stabilize IκB-α by inhibiting its ubiquitination, thereby blocking the nuclear translocation of NF-κB p65. Conclusions: NaHS mitigates OVX-induced bone loss via dual inhibition of osteoclast differentiation (through IκB-α/NF-κB blockade) and bone resorption. Its capacity to circumvent the limitations of current therapies positions NaHS as a novel candidate for osteoporosis management.
- Open Access
Bypassing the Heat Risk and Efficacy Limitations of Pulsed 630 nm LED Photobiomodulation Therapy for Anti-Primary Dysmenorrhea: A Prospective Randomized Cross-Over Trial
In recent years, photobiomodulation (PBM) has attracted widespread attention for the treatment of various causes of pain and inflammation. Primary dysmenorrhea (PD) is a common gynecological condition characterized by severe menstrual pain, and the limited effectiveness and side effects of conventional treatments have highlighted the urgent need to develop and identify new adjunct therapeutic strategies. The present study from the perspective of light morphology aimed to bypass the heat risk limitation and evaluate the efficacy and safety of pulsed 630 nm PBM therapy for reducing pain associated with PD. The pulse light parameters were designed according to the transmittance of red light. In this randomized, cross-over design, sham-controlled study, 46 women with PD were included and randomly assigned to either pulsed 630 nm light therapy or white light sham control therapy. The intervention lasted for 20 min per day and was administered for 7 consecutive days before and during menstruation. The results showed that the pulsed 630 nm PBM treatment demonstrated a significant reduction in pain levels compared to the placebo treatment (p < 0.001), with 55.00% of active treatment participants experiencing a pain intensity differential concentration exceeding 50.00%. Moreover, participants reported an improved quality of life during the active treatment phase and generally preferred it as a more effective method for relieving PD. No adverse events or side effects were reported throughout the trial. Based on the results, pulsed 630 nm LED therapy showed significant relief of menstrual pain compared to white light placebo treatment and improved quality of life under certain circumstances. Therefore, this study proposes that pulsed red light PBM therapy may be a promising approach for future clinical treatment of PD.
Open AccessBypassing the Heat Risk and Efficacy Limitations of Pulsed 630 nm LED Photobiomodulation Therapy for Anti-Primary Dysmenorrhea: A Prospective Randomized Cross-Over Trial
In recent years, photobiomodulation (PBM) has attracted widespread attention for the treatment of various causes of pain and inflammation. Primary dysmenorrhea (PD) is a common gynecological condition characterized by severe menstrual pain, and the limited effectiveness and side effects of conventional treatments have highlighted the urgent need to develop and identify new adjunct therapeutic strategies. The present study from the perspective of light morphology aimed to bypass the heat risk limitation and evaluate the efficacy and safety of pulsed 630 nm PBM therapy for reducing pain associated with PD. The pulse light parameters were designed according to the transmittance of red light. In this randomized, cross-over design, sham-controlled study, 46 women with PD were included and randomly assigned to either pulsed 630 nm light therapy or white light sham control therapy. The intervention lasted for 20 min per day and was administered for 7 consecutive days before and during menstruation. The results showed that the pulsed 630 nm PBM treatment demonstrated a significant reduction in pain levels compared to the placebo treatment (p < 0.001), with 55.00% of active treatment participants experiencing a pain intensity differential concentration exceeding 50.00%. Moreover, participants reported an improved quality of life during the active treatment phase and generally preferred it as a more effective method for relieving PD. No adverse events or side effects were reported throughout the trial. Based on the results, pulsed 630 nm LED therapy showed significant relief of menstrual pain compared to white light placebo treatment and improved quality of life under certain circumstances. Therefore, this study proposes that pulsed red light PBM therapy may be a promising approach for future clinical treatment of PD.
- Open Access
- 22 December 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 212, 65-79
SOD3 regulates FLT1 to affect bone metabolism by promoting osteogenesis and inhibiting adipogenesis through PI3K/AKT and MAPK pathways
- 22 December 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 212, 65-79
Open AccessSOD3 regulates FLT1 to affect bone metabolism by promoting osteogenesis and inhibiting adipogenesis through PI3K/AKT and MAPK pathways
- 15 February 2023
- Published by Springer Nature in Lasers in Medical Science
- Vol. 38 (1) , 1-12
The pulse light mode enhances the effect of photobiomodulation on B16F10 melanoma cells through autophagy pathway
Photobiomodulation (PBM) is the use of low irradiance light of specific wavelengths to generate physiological changes and therapeutic effects. However, there are few studies on the effects of PBM of different LED light modes on cells. Here, we investigated the difference of influence between continuous wave (CW) and pulse-PBM on B16F10 melanoma cells. Our results suggested that the pulse mode had a more significant PBM than the CW mode on B16F10 melanoma cells. Our study confirmed that ROS and Ca2+ levels in B16F10 melanoma cells treated with pulse-PBM were significantly higher than those in the control and CW-PBM groups. One mechanism that causes the difference in CW and pulse-PBM action is that pulse-PBM activates autophagy of melanoma cells through the ROS/OPN3/Ca2+ signaling pathway, and excessive autophagy activation inhibits proliferation and apoptosis of melanoma cells. Autophagy may be one of the reasons for the difference between pulse- and CW-PBM on melanoma cells. More importantly, melanoma cells responded to brief PBM pulses by increasing intracellular Ca2+ levels.
- 15 February 2023
- Published by Springer Nature in Lasers in Medical Science
- Vol. 38 (1) , 1-12
The pulse light mode enhances the effect of photobiomodulation on B16F10 melanoma cells through autophagy pathway
Photobiomodulation (PBM) is the use of low irradiance light of specific wavelengths to generate physiological changes and therapeutic effects. However, there are few studies on the effects of PBM of different LED light modes on cells. Here, we investigated the difference of influence between continuous wave (CW) and pulse-PBM on B16F10 melanoma cells. Our results suggested that the pulse mode had a more significant PBM than the CW mode on B16F10 melanoma cells. Our study confirmed that ROS and Ca2+ levels in B16F10 melanoma cells treated with pulse-PBM were significantly higher than those in the control and CW-PBM groups. One mechanism that causes the difference in CW and pulse-PBM action is that pulse-PBM activates autophagy of melanoma cells through the ROS/OPN3/Ca2+ signaling pathway, and excessive autophagy activation inhibits proliferation and apoptosis of melanoma cells. Autophagy may be one of the reasons for the difference between pulse- and CW-PBM on melanoma cells. More importantly, melanoma cells responded to brief PBM pulses by increasing intracellular Ca2+ levels.
- Open Access
- 13 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1022973
Progress of phototherapy for osteosarcoma and application prospect of blue light photobiomodulation therapy
Osteosarcoma (OS) is the most common primary malignant bone tumor that mainly affects the pediatric and adolescent population; limb salvage treatment has become one of the most concerned and expected outcomes of OS patients recently. Phototherapy (PT), as a novel, non-invasive, and efficient antitumor therapeutic approach including photodynamic therapy (PDT), photothermal therapy (PTT), and photobiomodulation therapy (PBMT), has been widely applied in superficial skin tumor research and clinical treatment. OS is the typical deep tumor, and its phototherapy research faces great limitations and challenges. Surprisingly, pulse mode LED light can effectively improve tissue penetration and reduce skin damage caused by high light intensity and has great application potential in deep tumor research. In this review, we discussed the research progress and related molecular mechanisms of phototherapy in the treatment of OS, mainly summarized the status quo of blue light PBMT in the scientific research and clinical applications of tumor treatment, and outlooked the application prospect of pulsed blue LED light in the treatment of OS, so as to further improve clinical survival rate and prognosis of OS treatment and explore corresponding cellular mechanisms.
- 13 October 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1022973
Open AccessProgress of phototherapy for osteosarcoma and application prospect of blue light photobiomodulation therapy
Osteosarcoma (OS) is the most common primary malignant bone tumor that mainly affects the pediatric and adolescent population; limb salvage treatment has become one of the most concerned and expected outcomes of OS patients recently. Phototherapy (PT), as a novel, non-invasive, and efficient antitumor therapeutic approach including photodynamic therapy (PDT), photothermal therapy (PTT), and photobiomodulation therapy (PBMT), has been widely applied in superficial skin tumor research and clinical treatment. OS is the typical deep tumor, and its phototherapy research faces great limitations and challenges. Surprisingly, pulse mode LED light can effectively improve tissue penetration and reduce skin damage caused by high light intensity and has great application potential in deep tumor research. In this review, we discussed the research progress and related molecular mechanisms of phototherapy in the treatment of OS, mainly summarized the status quo of blue light PBMT in the scientific research and clinical applications of tumor treatment, and outlooked the application prospect of pulsed blue LED light in the treatment of OS, so as to further improve clinical survival rate and prognosis of OS treatment and explore corresponding cellular mechanisms.
- 30 October 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-8
Anemia is related to osteoporosis in Chinese type 2 diabetic patients
Summary Both anemia and osteoporosis are common in type 2 diabetes mellitus (T2DM). However, the relationship between them remains to be determined. This study showed that anemia was related to osteoporosis in male and female T2DM patients. Diabetes patients with anemia should also be wary of osteoporosis. Introduction Anemia and osteoporosis are considered complications of type 2 diabetes mellitus (T2DM). However, the relationship between anemia and osteoporosis in the T2DM population remains to be determined. Thus, we planned the present study to verify their relationship. Methods A retrospective cross-sectional study was performed. The patients were divided into groups according to sex and hemoglobin levels (Q1: ≤ 120, Q2: 120 to ≤ 140, Q3: > 140 in men; Q1: ≤ 110, Q2: 110 to ≤ 130, Q3: > 130 in women). Clinical characteristics and bone mineral density (BMD) were compared. The relationship between anemia and osteoporosis was determined after adjusting for age, diabetic duration, body mass index, alanine aminotransferase, creatinine, HbA1c, and fasting C-peptide. Statistical analysis was performed using SPSS 26.0. Results This study included 2336 patients (1150 men and 1186 postmenopausal women). The percentage of osteoporosis differed by hemoglobin status in both men (Q1: 20.2%, Q2: 15.5%, Q3: 12.4%, P = 0.031) and women (Q1: 51.4%, Q2: 38.0%, Q3: 34.5%, P < 0.001). Q1, with the lowest hemoglobin level, has higher percentage of osteoporosis in men (20.2%) and in women (51.4%). Hip BMD (men: r = 0.168, P < 0.001, women: r = 0.126, P < 0.001) and femur neck BMD (men: r = 0.150, P < 0.001, women: r = 0.134, P < 0.001) were correlated with hemoglobin levels in both sexes. The odds of osteoporosis increased 1.4-fold in men and 2.0-fold in women in the Q1 groups compared with Q3 groups. Conclusion Anemia was related to osteoporosis in T2DM patients regardless of sex. Diabetic patients with anemia (men with hemoglobin below 120 g/L and women with hemoglobin below 110 g/L) should also be wary of osteoporosis.
- 30 October 2021
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 16 (1) , 1-8
Anemia is related to osteoporosis in Chinese type 2 diabetic patients
Summary Both anemia and osteoporosis are common in type 2 diabetes mellitus (T2DM). However, the relationship between them remains to be determined. This study showed that anemia was related to osteoporosis in male and female T2DM patients. Diabetes patients with anemia should also be wary of osteoporosis. Introduction Anemia and osteoporosis are considered complications of type 2 diabetes mellitus (T2DM). However, the relationship between anemia and osteoporosis in the T2DM population remains to be determined. Thus, we planned the present study to verify their relationship. Methods A retrospective cross-sectional study was performed. The patients were divided into groups according to sex and hemoglobin levels (Q1: ≤ 120, Q2: 120 to ≤ 140, Q3: > 140 in men; Q1: ≤ 110, Q2: 110 to ≤ 130, Q3: > 130 in women). Clinical characteristics and bone mineral density (BMD) were compared. The relationship between anemia and osteoporosis was determined after adjusting for age, diabetic duration, body mass index, alanine aminotransferase, creatinine, HbA1c, and fasting C-peptide. Statistical analysis was performed using SPSS 26.0. Results This study included 2336 patients (1150 men and 1186 postmenopausal women). The percentage of osteoporosis differed by hemoglobin status in both men (Q1: 20.2%, Q2: 15.5%, Q3: 12.4%, P = 0.031) and women (Q1: 51.4%, Q2: 38.0%, Q3: 34.5%, P < 0.001). Q1, with the lowest hemoglobin level, has higher percentage of osteoporosis in men (20.2%) and in women (51.4%). Hip BMD (men: r = 0.168, P < 0.001, women: r = 0.126, P < 0.001) and femur neck BMD (men: r = 0.150, P < 0.001, women: r = 0.134, P < 0.001) were correlated with hemoglobin levels in both sexes. The odds of osteoporosis increased 1.4-fold in men and 2.0-fold in women in the Q1 groups compared with Q3 groups. Conclusion Anemia was related to osteoporosis in T2DM patients regardless of sex. Diabetic patients with anemia (men with hemoglobin below 120 g/L and women with hemoglobin below 110 g/L) should also be wary of osteoporosis.
- 5 August 2021
- Published by Taylor & Francis in Chronobiology International
- Vol. 38 (12) , 1776-1785
Exploring the effects of large-area dorsal skin irradiation on locomotor activity and plasm melatonin level in C3H/He mice
As the largest organ exposed to the outside of mammals, skin has direct photosensitivity. Recent studies have even shown that cutaneous irradiation played a role in local circadian systems. However, whether it can further affect the central clock system is controversial. Here, plasm melatonin rhythm of melatonin-proficient C3H/He mice was assessed, and on this basis, a well-designed segmented lighting method was used to investigate the effects of dorsal skin irradiation on locomotor activity and plasm melatonin content in male C3H/He mice. In brief, mice were separately exposed to cutaneous irradiation, intraocular irradiation or darkness for 60 min at specific moments. The results showed that neither blue nor red cutaneous exposure had obvious effect on central rhythm oscillation while intraocular irradiation could significantly change the central clock of mice, and the effect of blue light was more forceful than red light. It suggests that intraocular nonvisual channels still play a dominant role in rhythmic regulation, which has not been challenged by the discovery of local light entrainment in exposed peripheral tissues.
- 5 August 2021
- Published by Taylor & Francis in Chronobiology International
- Vol. 38 (12) , 1776-1785
Exploring the effects of large-area dorsal skin irradiation on locomotor activity and plasm melatonin level in C3H/He mice
As the largest organ exposed to the outside of mammals, skin has direct photosensitivity. Recent studies have even shown that cutaneous irradiation played a role in local circadian systems. However, whether it can further affect the central clock system is controversial. Here, plasm melatonin rhythm of melatonin-proficient C3H/He mice was assessed, and on this basis, a well-designed segmented lighting method was used to investigate the effects of dorsal skin irradiation on locomotor activity and plasm melatonin content in male C3H/He mice. In brief, mice were separately exposed to cutaneous irradiation, intraocular irradiation or darkness for 60 min at specific moments. The results showed that neither blue nor red cutaneous exposure had obvious effect on central rhythm oscillation while intraocular irradiation could significantly change the central clock of mice, and the effect of blue light was more forceful than red light. It suggests that intraocular nonvisual channels still play a dominant role in rhythmic regulation, which has not been challenged by the discovery of local light entrainment in exposed peripheral tissues.